Jeff Meeusen, Ph.D., Published in ATVB

By Gina Chiri-Osmond • June 19, 2018

Share this:

Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine, recently had his paper, “Plasma Ceramides—A Novel Predictor of Major Adverse Cardiovascular Events after Coronary Angiography” accepted by the peer-reviewed journal Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), part of the American Heart Association’s group of journals. The paper was published earlier this week.

What Are Plasma Ceramides?
The team’s research discusses plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes. Ceramides can predict a patient’s risk for heart attack, stroke, and death within four years. Risk conferred is independent of cholesterol, age, sex, hypertension, smoking, and the presence of coronary artery stenosis. Dr. Meeusen says that ceramides can be lowered through exercise, diet, and the use of statins.

Gina Chiri-Osmond

Gina Chiri-Osmond is a Marketing Channel Manager at Mayo Clinic Laboratories.